ArticleEuropean journal of clinical pharmacology2026
Effects of ABC transporter polymorphism on the pharmacokinetics of pentoxifylline and its active metabolites in healthy Chinese subjects.
Article in European journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeThe objective of this study was to evaluate the influence of genetic polymorphisms in drug transporters on the pharmacokinetics of pentoxifylline (PTX) and its key active metabolites in a healthy Chinese population. SUBJECTS AND
methodsForty-six healthy Chinese volunteers were enrolled and took oral administration of 400 mg pentoxifylline. Plasma concentrations of PTX and its active metabolites (M1 and M5) were determined using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Genotyping of ABCB1 (3435C>T, 1236C>T, 2677G>T/A), ABCG2 (421C>A, 34G>A), and ABCC2 (-24C>T, 1249G>A, 3972C>T) was performed using the SnapShot technique.
resultsUnder fasting conditions, subjects carrying the ABCB1 3435C/T genotype demonstrated a significantly lower AUC (P < 0.05, Bonferroni-corrected) and a higher CL/F (P < 0.01, Bonferroni-corrected) of PTX compared to those carrying the ABCB1 3435C/C genotype. Furthermore, carriers of the ABCB1 3435C/T genotype exhibited a significantly higher metabolic conversion rate to M5 (P < 0.05, Bonferroni-corrected). Similarly, subjects with the ABCB1 2677(A/A+A/T) genotypes also showed a higher M5 conversion rate (P < 0.05, Bonferroni-corrected).
conclusionThe ABCB1 3435C>T and 2677G>T/A polymorphisms are associated with variations in the pharmacokinetics of PTX and its active metabolites.
Indexed as
Identifiers
41553547What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.